Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
09 December 2022 | Story Leonie Bolleurs | Photo Leonie Bolleurs
Dr Refilwe Mogale
Dr Refilwe Mogale received her PhD in Chemistry. She is fascinated by the ability of chemistry and science in general to solve some of the world’s most pressing issues, such as water scarcity.

“Chemistry chose me,” says Dr Refilwe Mogale, who wanted to enrol for Psychology years ago when she decided to study at the University of the Free State (UFS). 

“On the day of registration, however, as I was standing in the queue, something inside me said this was not the right choice for me. Ultimately, I chose my second option, which was a BSc degree majoring in biology, physics, and chemistry.”

“Once I started the BSc programme, I gravitated towards chemistry, and as difficult as it was juggling classes and six-hour practical sessions, I loved it. I am fascinated by the ability of chemistry and science in general to solve some of the world’s most pressing issues, such as water scarcity, alternative generation, access to antibacterial hygiene products, as well as novel strategies to cure diseases, among many other things.”

The UFS awarded Dr Mogale a PhD in Chemistry on 9 December 2022.

Addressing a global challenge

Being passionate about applied chemistry – where scientific research can be used to create products to address everyday problems – Dr Mogale focused her thesis on Aluminium- and Zirconium-based metal organic frameworks with azobenzene and stilbene dicarboxylate ligands for use in wastewater treatment. 

She has also published multiple articles on topics of environmental chemistry and wastewater management in international journals. 

Dr Mogale is of the opinion that water pollution by financially lucrative industries and access to clean drinkable water is one of our planet’s most challenging environmental and health issues. “The waste generated by some of the industries that contribute heavily to our country’s economy, such as the textile, agricultural, and medical industries, may end up in the limited drinking water resources we have. I chose my research topic because I wanted to positively contribute to this global challenge,” she says.

“My research was based on making highly porous metal-organic frameworks (MOF) to be used in the wastewater treatment technique called adsorption,” explains Dr Mogale, describing MOFs as “really cool three-dimensional ‘sponges’ that can suck up very high amounts of gases and pollutants, trapping them in their pores. These trapped materials can later be released from the pores to be re-used when MOFs are exposed to certain stimuli.”

She continues, “Low cost and simplicity make this method attractive for industrial use. Considering our current energy crisis, other methods are not ideal, since they require large amounts of energy.” 

Focused on developing highly effective adsorbent for wastewater purification systems, Dr Mogale synthesised a novel MOF with one of the highest adsorption capacities compared to existing counterparts.

According to her, should MOFs with their incredibly high surface areas – which allow them to absorb more waste than their existing counterparts – be implemented in wastewater purification systems, they would be able to address the environmental issue of water pollution and the health issue of access to drinkable water.

Tackling everyday societal issues

She is currently doing a postdoctoral fellowship in the UFS Department of Chemistry – to broaden her knowledge in chemistry beyond MOFs. Her plans are, however, to transition to industry and ultimately entrepreneurship, where she will be able to develop scientific products that can tackle everyday societal issues. 

Dr Mogale dreams of adding value to society by practically contributing to the water crisis issue through the development of low-cost water generation and purification products.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept